Lefteris Mylonakis retweeted
Program Available: 7th International Conference on #ModelHosts in #Crete #Greece from Oct. 12-17. Registration still open! aegeanconferences.org/src/Ap…
3
1
7
1,278
Lefteris Mylonakis retweeted
Had a great first visit (in this role) to @WeillCornell partners @MethodistHosp Enjoyed hearing about academic programs. Appreciate the 20 year relationship and Dean Gotto’s vision. Thanks to @WilliamZoghbi and Dr Mylonakis
3
5
54
4,522
🚨⏰🔔😳‼️😳🔔⏰🚨 How much ongoing regulatory training do academic professors need every year? After completing many hours of CITI training for clinical research/hospital with 16 modules on different topics with a detailed module on different types of COI (including COI outside the conduct of clinical research), now I need to complete overdue COI training for academic department/university. How much COI training is needed with ongoing disclosure requirements and oversight in place. Our academicians especially physician-scientists need to be able to do their work and not be constantly asked to repeat training on a never ending list of topics. Much time is already spent on grant writing in an often futile cycle due to low funding rates and limited resources. Grant reporting has also gotten more complex and time-consuming. The system is in desperate need of reform. @nasem @NIH @AmericanCancer @ASCO @AACR @theNCI @TheCancerLetter @ScienceMagazine @Nature
4
12
2
65
28,653
Is infectious disease consultation cost-effective for the management of Staphylococcus aureus bacteremia? 🆕⚡Economic evaluation using a decision-analytic model might provide an answer! #IDTwitter #MedEd #TwitteRx #MedTwitter jamanetwork.com/journals/jam…
2
19
1
61
Lefteris Mylonakis retweeted
An analysis in OFID found significant variability in mortality and impact of COVID-19 between countries in the #EuropeanUnion, even if they shared the same regulatory framework. 📄: https://nitter.cf/t.co/gc1ZMPqrHy #IDSAJournals #OpenForumInfectDis @PaulSaxMD @DrJLi @ElMylonakis
Lefteris Mylonakis retweeted
What would have the biggest impact on increasing US vaccinations isn't incentives, lotteries, or conveniences. It is @US_FDA giving vaccines full licensure, setting up requirements by military, health systems, & employers. That may happen sooner than anticipated. Like next month
71
158
30
907
Lefteris Mylonakis retweeted
Two million-plus petitions were sent to the White House in hopes of convincing the Biden administration to support a proposal that would temporarily waive trade agreement provisions in a bid to widen access to Covid-19 vaccines in low-income countries. buff.ly/3euuAht
1
64
8
173
Lefteris Mylonakis retweeted
Two new @CDCMMWR reports underscore the need to address health inequities in our country & our #COVID19 vaccination efforts. We must commit to equitable distribution of vaccines, particularly to those communities that have increased risk for COVID-19. https://nitter.cf/t.co/6NjSpPgYMe
60
49
7
203
Lefteris Mylonakis retweeted
No data suggesting lower efficacy of AstraZeneca vaccine: German health ministry reut.rs/3a1TKSx
5
36
7
77
The Massachusetts Department of Public Health today announced that the first case of the COVID-19 variant B.1.1.7 has been detected in Massachusetts. This is the same variant initially discovered in the United Kingdom. mass.gov/news/department-of-…
2
5
1
12
Lefteris Mylonakis retweeted
Sinovac's CoronaVac vaccine has been bought by countries with promises of high efficacy Brazil just burst that bubble Brazilian researchers report the CoronaVac efficacy is 50.4% This is why we need published phase 3 trials before celebrations www1.folha.uol.com.br/equili…
11
131
48
226
Lefteris Mylonakis retweeted
We mapped how all mutations to #SARSCoV2 receptor-binding domain (RBD) affect recognition by convalescent polyclonal human sera (biorxiv.org/content/10.1101/…). Among implications: E484K (South African lineage) worrying for immune escape; RBD mutations in UK lineage less so (1/n).
43
747
260
1,554
Lefteris Mylonakis retweeted
The world is “losing its ability” to use “critically important” antibiotics, says @DrTedros. And #COVID19 is making this worse. But the number of countries tracking resistant infections has tripled in 2 years, reports @WHO. This data can #StopSuperbugs who.int/news-room/detail/01-…
8
37
5
91
Lefteris Mylonakis retweeted
US Nat'l Academies zoom Tues-Fri on long-term impact of AMR. Tues - push and pull incentives (agenda below); Wed - diagnostics; Thurs - stewardship, including alternatives in agriculture; Friday - anthropology & global burden of AMR. Register (free) here: nationalacademies.org/event/…
Replying to @rafaaraos
Hola, here is your unroll: The following info is directly from who.int/csr/don/31-dec… & thehealthsite.com/news/who-r…… Commentary and info… threadreaderapp.com/thread/1… Have a good day. 🤖
Lefteris Mylonakis retweeted
Here's a chart of the percentage of distributed Covid-19 vaccine doses that have been administered (from latest CDC data yesterday — thanks @DataDrivenMD for the data help). In addition to Bureau of Prisons (a federal agency), SD, DC, CT, ND and ME are in the top 5.
16
26
20
50
Lefteris Mylonakis retweeted
Do you think SARS-CoV-2 Lineage B.1.1.7 is now in your state?
90%Yes
0%No
10%Will be within 2 weeks
0%Already found(CO, CA, FL)
10 votes • Final results
BREAKING: from the Royal London Hospital, this email from management👇 “We are now in disaster medicine mode. We are no longer providing high standard critical care, because we cannot” The content of this email is SHOCKING and I’m passing it to a trusted journalist right now🚨
797
10,037
1,228
22,664
Lefteris Mylonakis retweeted
Simply put, the whole world needs to have access to vaccination. We are all in the same leaky boat. It is both an injustice and a risk for us all if COVID persists anywhere.
La pandemia será un punto de inflexión para la humanidad, sin embargo, como muestra este mapa, la desigualdad no se acabará pronto y probablemente solo aumente. Las inequidades regionales serán significativas en la disponibilidad de vacunas. Esto tendrá un impacto en la cirugía.
1
13
1
38
Calling it a "UTI" is nonspecific and has no place in clinical medicine. The history, etiology, diagnosis, and management are different for urethritis, prostatitis, epididymo-orchitis, cystitis, and pyelonephritis, and should be addressed as such. I will die on this hill
14
41
5
332